AB048. Evidence of effectiveness of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas
This immuno-target combination neoadjuvant therapy in recurrent HGG demonstrated encouraging efficacy and revealed some evidence of efficacy, and worth to further investigate.
Authors
- Xiaobing Jiang (ORCID: https://orcid.org/0000-0001-6566-7269)
- Fuhua Lin
- Shaoyan Xi
- De‐Pei Li (ORCID: https://orcid.org/0000-0002-4801-2452)
- Yingsheng Chen
- Qunying Yang (ORCID: https://orcid.org/0000-0001-9018-8067)
- Wanming Hu
- Jiang Zhou (ORCID: https://orcid.org/0000-0003-1038-387X)
- Chengcheng Guo (ORCID: https://orcid.org/0000-0003-0857-0350)
- Ji Zhang (ORCID: https://orcid.org/0000-0001-9649-9608)
- Chao Ke (ORCID: https://orcid.org/0000-0003-1918-9600)
- Zhihuan Zhou (ORCID: https://orcid.org/0000-0002-1738-064X)
- Shengnan Ceng
- Zhongping Chen
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/cco-24-ab048
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00